Zonisamide

Zonisamide (AD 810) is an orally active carbonic anhydrase inhibitor, with Kis of 35.2 and 20.6 nM for hCA II and hCA V, respectively. Zonisamide exerts neuroprotective effects through anti-apoptosis and upregulating MnSOD levels. Zonisamide also increases the expression of Hrd1, thereby improving cardiac function in AAC rats. Zonisamide can be used in studies of seizure, parkinson’s disease and cardiac hypertrophy[1][2][3][4].

Product Specifications

CAS Number

[68291-97-4]

Product Name Alternative

AD 810; CI 912

UNSPSC

12352005

Hazard Statement

H302, H361

Target

Apoptosis; Carbonic Anhydrase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/zonisamide.html

Purity

99.94

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : 0.67 mg/mL (ultrasonic)

Smiles

O=S(CC1=NOC2=C1C=CC=C2)(N)=O

Molecular Formula

C8H8N2O3S

Molecular Weight

212.23

Precautions

H302, H361

References & Citations

[1]Kawajiri S, et al. Zonisamide reduces cell death in SH-SY5Y cells via an anti-apoptotic effect and by upregulating MnSOD. Neurosci Lett. 2010 Sep 6;481 (2) :88-91. |[2]Ueda Y, et al. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003 Aug 19;116 (1-2) :1-6. |[3]Wu Q, et al. Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress. Acta Pharmacol Sin. 2021 Oct;42 (10) :1587-1597.|[4]De Simone G, et al. Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: solution and X-ray crystallographic studies. Bioorg Med Chem Lett. 2005 May 2;15 (9) :2315-20.